Adverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual Meeting

Core Viewpoint - Adverum Biotechnologies is advancing gene therapy as a potential new standard of care for wet age-related macular degeneration (wet AMD) and will present interim data from its LUNA Phase 2 study at the ASRS Annual Scientific Meeting [1][2]. Company Overview - Adverum Biotechnologies (NASDAQ:ADVM) is a clinical-stage company focused on developing gene therapies for prevalent ocular diseases, aiming to create functional cures to restore vision and prevent blindness [4]. - The company is leveraging its proprietary intravitreal (IVT) platform to develop durable, single-administration therapies that can be delivered in physicians' offices, reducing the need for frequent ocular injections [4]. Upcoming Events - A webcast will be held on July 17, 2024, at 8:00 a.m. ET to review the interim 26-week data from the LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) [1]. - Dr. Charles C. Wykoff will present the findings during the Wet AMD Symposium at the ASRS Annual Scientific Meeting on the same day at 8:45 a.m. CEST [2]. Presentation Access - The live webcast will be available on the company's website, and a replay will be accessible for at least 30 days following the event [3].